Paper494379
In vitro generation of primary cytotoxic lymphocytes against L5178Y leukemia antigenically altered by 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide in vivo.
Romani L and 2 others. Transplantation, 1979. Cited by 33 papers, by iCite.
Cite this record
ConductScience Library. In vitro generation of primary cytotoxic lymphocytes against L5178Y leukemia antigenically altered by 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide in vivo. Papers, record 494379. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/494379
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- In vitro generation of primary cytotoxic lymphocytes against L5178Y leukemia antigenically altered by 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide in vivo.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antigens | Major topic |
| Cytotoxicity, Immunologic | Major topic |
| Dacarbazine | Major topic |
| Leukemia L5178 | Major topic |
| Leukemia, Experimental | Major topic |
| Lymphocytes | Major topic |
| Animals | |
| Kinetics | |
| Lymphoma | |
| Mice | |
| Mice, Inbred BALB C | |
| Mice, Inbred DBA | |
| Mice, Nude | |
| Spleen |
Source PubMed
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 18925393 | Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. | Cancer Immunol Immunother | 2009 | https://conductscience.org/library/papers/18925393 | PubMed |
| 8635195 | Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL). | Cancer Immunol Immunother | 1995 | https://conductscience.org/library/papers/8635195 | PubMed |
| 6561067 | Immunogenic changes of murine lymphoma cells following in vitro treatment with aryl-triazene derivatives. | Cancer Immunol Immunother | 1984 | https://conductscience.org/library/papers/6561067 | PubMed |
| 3297373 | Chemical xenogenization of experimental tumors. | Cancer Metastasis Rev | 1987 | https://conductscience.org/library/papers/3297373 | PubMed |
| 3257903 | Cell-mediated immunity to chemically xenogenized tumors. I. Inhibition by specific antisera and H-2 association of the novel antigens. | Cancer Immunol Immunother | 1988 | https://conductscience.org/library/papers/3257903 | PubMed |
| 2791188 | Two antiemetic regimens do not impair chemical xenogenization induced in vivo by 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide. | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2791188 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/494379
GET https://conductscience.org/api/papers/v1/494379/authors